Clinical trial

Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma

NCT06220032

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2024-08-15

PhasePHASE3

Study timeline

Study start (actual)2024-08-15Date precision: day

Registry last updated2026-09-23

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

DLBCL - Diffuse Large B Cell Lymphomaunresolved

Interventions

DexrazoxaneDRUG · verified · RxNorm: dexrazoxane

RituximabDRUG · verified · RxNorm: rituximab

CyclophosphamideDRUG · verified · RxNorm: cyclophosphamide

DoxorubicinDRUG · verified · RxNorm: doxorubicin

VincristineDRUG · verified · RxNorm: vincristine

PrednisoloneDRUG · verified · RxNorm: prednisolone

LenalidomideDRUG · verified · RxNorm: lenalidomide

PegfilgrastimDRUG · verified · RxNorm: pegfilgrastim

Sponsors & collaborators

Stichting Hemato-Oncologie voor Volwassenen Nederlandlead sponsor

UMC Utrechtcollaborator

Amsterdam UMC, location VUmccollaborator

The Dutch Network for Cardiovascular Research (WCN)collaborator

Mapped research locations

GroningenNetherlands1 RotterdamNetherlands1 NijmegenNetherlands1 UtrechtNetherlands1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06220032 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.